Ifosfamide and Etoposide in the Treatment of Advanced Soft Tissue Sarcomas

Blair, Scott C.; Zalupski, Mark M.; Baker, Laurence H.

doi:10.1097/00000421-199412000-00005

Cited by 33 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal stromal tumors as a group appear to be very resistant to conventional cytotoxic agents. 16,38,48 However, intraperitoneal chemotherapy is currently being investigated as a treatment for intra-abdominal recurrence. 34,49 In conclusion, GIST of the small intestine carries a high mortality rate, with only 28% of patients in our series alive at a median follow-up of 20 months, and only 12% without disease.…”

Section: Discussionmentioning

confidence: 99%

Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

et al. 2001

View full text Add to dashboard Cite

Most patients with M-GIST of the small intestine relapse following resection, but survival may be prolonged. In univariable analysis, stage at presentation and complete resection were significant prognostic variables for OS; grade was not significant. Localized and locally advanced M-GIST of the small intestine have a mean OS > 5 years. Complete resection should be the goal of initial surgical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Imatinib is a potent inhibitor of KIT signaling tyrosine kinase inhibitor (5,6,10,20,29) . Before the use of imatinib, the median survival of the patients with resectable disease was 66 months (5,9) and 9 to 12 months in irresectable disease (3,4,9,11,12,14,38) .…”

Section: Introductionmentioning

confidence: 99%

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Neves¹,

Oshima²,

Neto³

et al. 2009

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Cellular proliferation and apoptosis is gaining importance for predicting prognosis in several cancers. Objective -To investigate the Ki67 and p53 immunostaining in GISTs. Methods -Specimens from 40 patients with GIST were assessed for immunohistochemical expression of Ki67 and p53. The tumors were divided according the risk of recurrence in two groups: I with high or intermediate risk and; II with low or very low risk. Results -Among the 40 patients, 21 were men, the mean age was 56 years, 16 occurred in the small intestine and 13 in the stomach, 5 in the retroperitonium, 4 in the colon or rectum and 2 in the mesenterium. Thirty two tumors were from group I and 8 from group II. Half of the patients developed recurrence, being 90% of the group I (P = 0.114). The tumor Ki67 labelling index ranged from 0.02 to 0.35 (mean level 0.12). This index was marginally higher in the group I patients with recurrence (P = 0.09) compared to the patients of the same group without recurrence. p53 staining was expressed in 65% of the GISTs. A higher frequency of p53 and Ki67 had been found in the group I tumors when compared to the other group (P = 0.022; OR = 8.00 -IC 95%: 1.32-48.65). Conclusion -The most common site was the small intestine and 80% had a malignant potential justifying the high recurrence observed. No significant correlation was found between p53 and overall outcome of the patients. In group I patients, the evaluation Ki67LI may be a marker of prognosis. The positivity of both markers is higher among the patients with worst prognosis than in the others. HEADINGS -Gastrointestinal stromal tumors. Ki-67 antigen. Tumor suppressor protein p53.

show abstract

“…La quimioterapia sistémica no ha sido efectiva. Hay algunos estudios con baja tasa de respuesta a combinaciones de doxorrubicina y dacarbacina 39 , dacarbacina más mitomicina c, doxorrubicina y cisplatino 40 y no hay respuesta a etopósido e ifosfamida 41 . La falta de respuesta a las drogas usualmente usadas en sarcomas de partes blandas se debería a la frecuente expresión de la glicoproteína P y proteína a multiresistencia a drogas 1(MDR1) en estos tumores, relacionados con la resistencia a drogas 42 .…”

Section: Factores Pronóstico Clínicos Y Patológicosunclassified

Tumores del estroma gastrointestinal (GIST), un particular tipo de neoplasia

2008

Rev. méd. Chile

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIS) are a heterogeneous group of tumors that express CD (Rev Méd Chile 2008; 136: 921-9L as primeras descripciones de tumores mesenquimáticos del tracto gastrointestinal datan de la década del 40 1 . Durante años fueron clasificados como tumores derivados de células musculares lisas basados en el parecido histológico con estas células, así fueron llamados leiomiomas bizarros, leiomiomas celulares y leiomiosarcomas 2 .Con el advenimiento de la microscopia electrónica se demostró que sólo algunos de estos tumores mostraban evidencias ultraestructurales de presentar diferenciación muscular lisa. La caracterización inmunohistoquímica ha permitido conocer los distintos tipos de diferenciación que presentan estos tumores. En 1984, Herrera et al 3 describieron una diferenciación neuronal autonó-mica en algunos subtipos de este tumor que desde 1983, gracias al trabajo de Manzur y Clark 4 , se habían denominado genéricamente como "tumores estromales". Pese a los avances, aun en la década de los 80 persistían las dudas dado que estos tumores poseen diferenciación miogénica, neural, pero también pueden presentar diferenciación mixta o sencillamente no presentar diferenciación específica. Otro hito en la historia de esta enfermedad lo marcó Hirota et al. que en 1998 descubre mutaciones funcionantes en el protooncogén c-kit de los GIST, lo que permitió a la larga una clasificación adecuada de los tumores, así como el desarrollo de una novedosa terapia molecular dirigida contra la tirosina kinasa 5 .Se ha sugerido que los GIST se originan de las células intersticiales de Cajal o desde células precursoras primitivas que se diferencian hacia

show abstract

Ifosfamide and Etoposide in the Treatment of Advanced Soft Tissue Sarcomas

Cited by 33 publications

References 0 publications

Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Tumores del estroma gastrointestinal (GIST), un particular tipo de neoplasia

Contact Info

Product

Resources

About